Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ariad, Merck Submit Ridaforolimus MAA | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ariad, Merck Submit Ridaforolimus MAA

Oral treatment for sarcomas can trigger multiple milestones

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ariad Pharmaceuticals and Merck have submitted a marketing authorization application (MAA) for ridaforolimus with the EMA. Merck is planning global submissions for ridaforolimus in Europe, the U.S., Canada, Asia-Pacific and Latin America and other key markets. Acceptance of the MAA will trigger a $25 million milestone payment to Ariad. The company will also receive a $25 million milestone payment upon approval in the U.S., while approval to sell ridaforolimus in the EU will secure a $10 million milestone payment.

If approved, oral ridaforolimus, an investigational mTOR inhibitor, would be the first molecularly targeted drug for the treatment of patients with metastatic sarcomas and the first sarcoma drug to be approved for use as a maintenance therapy, according to Ariad.

“We are delighted by the submission for regulatory review of ridaforolimus in the EU,” said Harvey J. Berger, M.D., chairman and chief executive officer of Ariad. “We look forward to the submission of additional filings on ridaforolimus and to its review as a potential new treatment option for patients with metastatic soft-tissue and bone sarcomas.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters